SecBot SecBot
SECBOTREPLAY Home › Report › DYN

DYN · Dyne Therapeutics reported positive topline results from the Phase 1/2…

Dyne Therapeutics, Inc. · PRESS-RELEASE filed Mar 2, 2026 at 07:30 ET

At the news

BULLISHIMPACT 8/10

PRESS-RELEASE filed Mar 2, 2026 at 07:30 ET

Dyne Therapeutics reported positive topline results from the Phase 1/2 DELIVER trial of z-rostudirsen in Duchenne muscular dystrophy, showing statistically significant dystrophin expression and functional improvements. The company plans a Q2 2026 BLA submission for accelerated approval, with a potential U.S. launch in Q1 2027. Cash remains strong at $1.1 billion, supporting operations into Q1 2028, despite increased R&D and net losses.

  • Positive topline results from DELIVER trial: 5.46% normal dystrophin expression at 6 months (7-fold increase, p<0.0001); functional improvements in TTR and 10MWR vs. placebo (nominal p<0.05).
  • Z-rostudirsen safety profile remains favorable, with mostly mild-to-moderate treatment-related adverse events.
  • BLA submission for z-rostudirsen planned for Q2 2026; potential U.S. launch in Q1 2027 assuming Priority Review.
  • Enrollment in ACHIEVE trial for z-basivarsen in DM1 on track for completion in Q2 2026, with BLA submission expected in early Q3 2027.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access